HLAA Webinar: Potential New Therapies and Clinical Trial Opportunities for Sudden and Noise-Induced Sensorineural Hearing Loss

January 20, 2022 @ 2:00 pm – 3:00 pm
Join by computer or mobile device.

When: Thursday, January 20, 2022
Time: 2-3p.m. (ET) 

Are you interested in learning about new, emerging therapies that could potentially restore hearing? Would you like to stay apprised of new clinical trials for individuals with sensorineural hearing loss (SNHL) – and learn how to enroll?

In this program, Frequency Therapeutics’ Chief Development Officer, Dr. Carl LeBel, will provide an overview of outcomes from four completed clinical trials of FX-322, the Company’s product candidate, which is the first to have shown meaningful hearing improvements in clinical studies. Individuals that showed these improvements included those with a range of hearing loss severities and causes, and Dr. LeBel will discuss the types of hearing loss where Frequency is currently focused. Grace Fitzgerald, Director of Clinical Operations for Frequency, will share information about a current clinical trial for FX-322 with sites across the country and opportunities for individuals to enroll. A Q&A discussion will follow the presentation.

Frequency’s hearing program focuses on addressing the underlying cause of SNHL by regenerating cells in the ear that are necessary for healthy hearing.

Note: HLAA does not endorse products or services featured and the presentation is paid for by the presenting company.


Carl LaBel headshot Carl LeBel, Ph.D., has been the Chief Development Officer at Frequency Therapeutics since 2018. He started LeBel Consulting LLC after serving as the Chief Scientific Officer at Otonomy, Inc., from 2009 to 2016. Before joining Otonomy, he was President and CEO of Akesis Pharmaceuticals, Inc., a virtual metabolic disorders company, and prior to that spent more than 14 years at Amgen as an executive director in a variety of R&D management positions. Carl is a scientific fellow of the American Academy of Otolaryngology, and a full member of both the American Association for the Advancement of Science and the Society of Toxicology. Carl is also a co-inventor on numerous patents in the field of drug delivery for otology-related disorders.

Grace FitzgeraldGrace Fitzgerald has been the Director of Clinical Operations at Frequency Therapeutics since 2020. Prior to joining Frequency, Grace was at ICON overseeing large global phase III studies and at Otonomy, Inc. conducting trials that involve intratympanic delivery for Meniere’s Disease. She also had trial oversight responsibilities for pediatric trials in cisplatin-induced hearing loss and otitis media.


Registration is required for this event. After registering, you will receive a confirmation email containing information about joining the meeting.

Register for Webinar

Helpful Hints and Tutorials

    • Zoom concerns have been addressed and procedures will be modified as Zoom continues to update their software. The main security issue was with open meetings. When you register, it creates a unique link for a password protected session.
    • Use a computer. If possible, attend the meeting on a computer rather than via a smart phone or iPad. This will give you the best layout to view the captions as well as other meeting features.
  • Update Zoom. Make sure to upgrade to the latest version of Zoom.
  • Captions. HLAA Webinars are open or closed captioned. Subtitles will be visible at the bottom of the meeting zoom screen.
  • Check your time zone. This meeting will take place live at 2 p.m. ET, 1 p.m. CT, Noon MT and 11 a.m. PT. If you are in a different time zone, please adjust the time so you do not miss the meeting.
  • Questions? Feel free to email us at webinars@hearingloss.org.m. PT. If you are in a different time zone, please adjust the time so you do not miss the meeting.

NOTE: HLAA does not offer Continuing Education Units (CEUs) for participation in our webinars.

Questions? Feel free to email us at webinars@hearingloss.org.